Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of african green monkeys and chimpanzees

Virology

Volumn 297, Issue 1, 2002, Pages 153-160

  Skiadopoulos, M H ^a   Surman, S R ^a   Riggs, J M ^a   Elkins, W R ^a   St Claire, M ^b   Nishio, M ^c   Garcin, D ^c   Kolakofsky, D ^c   Collins, P L ^a   Murphy, B R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b BIOQUAL INC   (United States)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CERCOPITHECIDAE; CHIMPANZEE; CONTROLLED STUDY; DISEASE TRANSMISSION; HOST RANGE; LOWER RESPIRATORY TRACT; NONHUMAN; PARAINFLUENZA VIRUS 1; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SENDAI VIRUS; SPECIES COMPARISON; UPPER RESPIRATORY TRACT; VIRUS ISOLATION; VIRUS REPLICATION; ZOONOSIS;

CERCOPITHECUS AETHIOPS; HUMAN PARAINFLUENZA VIRUS 1; MURINAE; PAN (APE); PRIMATES; SENDAI VIRUS;

EID: 0036316695     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2002.1416     Document Type: Article

References (47)

1. Recent zoonoses caused by influenza A viruses
2. Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates
3. Molecular characterization of Menangle virus, a novel paramyxovirus which infects pigs, fruit bats, and humans
4. Parainfluenza viruses
5. Probable human infection with a newly described virus in the family Paramyxoviridae. The NSW Expert Group
6. Nipah virus: A recently emergent deadly paramyxovirus
7. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees
8. Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge
9. In vivo antigenic studies of parainfluenza viruses
10. African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection
11. Conserved and non-conserved regions in the Sendai virus genome: Evolution of a gene possessing overlapping reading frames
12. A point mutation in the Sendai virus accessory C proteins attenuates virulence for mice, but not virus growth in cell culture
13. Sendai virus contains overlapping genes expressed from a single mRNA
14. The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity
15. Newcastle Disease
16. Prevalence of various respiratory viruses in the middle ear during acute otitis media
17. Cloning and sequencing of the polymerase gene (P) of Sendai virus (strain 6/94)
18. Delayed clearance of Sendai virus in mice lacking class I MHC-restricted CD8+ T cells
19. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one
20. Sendai virus
21. Isolation of an avirulent mutant of Sendai virus with two amino acid mutations from a highly virulent field strain through adaptation to LLC-MK2 cells
22. Mutation of the HANA protein of Sendai virus by passage in eggs
23. An update on the "Jennerian" and modified "Jennerian" approach to vaccination of infants and young children against rotavirus diarrhea
24. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children
25. Attenuation of a field Sendai virus isolate through egg-passages is associated with an impediment of viral genome replication in mouse respiratory cells
26. Immediate protection of mice from lethal wild-type Sendai virus (HVJ) infections by a temperature-sensitive mutant, HVJpi, possessing homologous interfering capacity
27. Antigenic diversity of human parainfluenza virus type 1 isolates and their immunological relationship with Sendai virus revealed by using monoclonal antibodies
28. Newborn virus pneumonitis (type Sendai). II. Isolation of new virus possessing hemagglutinin activity
29. Half-life of human parainfluenza virus type 3 (hPIV3) maternal antibody and cumulative proportion of hPIV3 infection in young infants
30. The nucleoproteins of human parainfluenza virus type 1 and Sendai virus share amino acid sequences and antigenic and structural determinants
31. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/sendai virus vector boost regimen
32. Immunization against viral diseases
33. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses
34. Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus
35. A novel morbillivirus pneumonia of horses and its transmission to humans
36. Sequence analysis of the Washington/1964 strain of human parainfluenca virus type 1 (HPIV1) and recovery and characterization of wild type recombinant HPIV1 produced by reverse genetics
37. Outbreak of Nipah-virus infection among abattoir workers in Singapore
38. A field isolate of Sendai virus: Its high virulence to mice and genetic divergence form prototype strains
39. Human parainfluenza virus type 1 immunization of infant mice protects from subsequent Sendai virus infection
40. Infection of humans and horses by a newly described morbillivirus
41. Sequence of 3687 nucleotides from the 3′ end of Sendai virus genome RNA and the predicted amino acid sequences of viral NP, P and C proteins
42. Avian influenza viruses infecting humans
43. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1
44. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge
45. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus
46. A protease activation mutant, MVCES1, as a safe and potent live vaccine derived from currently prevailing Sendai virus
47. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates